Post-marketing Surveillance Study With MicardisPlus® in Treatment of Morning Hypertension (Self-monitored by Patient)

Boehringer Ingelheim2,707 enrolled

Overview

The purpose of the study was to examine the effect of six- to eight-week treatment with MicardisPlus® on blood pressure and the effect of patient self-monitoring on blood pressure control. In addition, the post-marketing surveillance study offered the possibility to obtain information about the influence on different laboratory parameters during treatment with MicardisPlus® from an unselected patient group under office conditions

Study Type

OBSERVATIONAL

Enrollment

2,707

Conditions

Hypertension

Interventions

MicardisPlus®DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \> 18 years * Hypertension Exclusion Criteria: * Age \< 18 years

Outcomes

Primary Outcomes

Changes in morning blood pressure (systolic and diastolic)

Time frame: Pre-dose, up to 8 weeks after start of treatment

Changes from baseline in laboratory values

Time frame: Pre-dose, up to 8 weeks after start of treatment

Investigator assessment of efficacy on a 5-point scale

Time frame: Up to 8 weeks after start of treatment

Investigator assessment of influence on metabolism on a 3-point scale

Time frame: Up to 8 weeks after start of treatment

Investigator assessment of tolerability on a 5-point scale

Time frame: Up to 8 weeks after start of treatment

Number of patients with adverse events

Time frame: Up to 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.